Literature DB >> 23159930

Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER⁺ breast tumors.

Andrea Clocchiatti1, Eros Di Giorgio, Sabrina Ingrao, Franz-Josef Meyer-Almes, Claudio Tripodo, Claudio Brancolini.   

Abstract

MEF2s transcription factors and class IIa HDACs compose a fundamental axis for several differentiation pathways. Functional relationships between this axis and cancer are largely unexplored. We have found that class IIa HDACs are heterogeneously expressed and display redundant activities in breast cancer cells. Applying gene set enrichment analysis to compare the expression profile of a list of putative MEF2 target genes, we have discovered a correlation between the down-regulation of the MEF2 signature and the aggressiveness of ER(+) breast tumors. Kaplan-Meier analysis in ER(+) breast tumors evidenced an association between increased class IIa HDACs expression and reduced survival. The important role of the MEF2-HDAC axis in ER(+) breast cancer was confirmed in cultured cells. MCF7 ER(+) cells were susceptible to silencing of class IIa HDACs in terms of both MEF2-dependent transcription and apoptosis. Conversely, in ER(-) MDA-MB-231 cells, the repressive influence of class IIa HDACs was dispensable. Similarly, a class IIa HDAC-specific inhibitor preferentially promoted the up-regulation of several MEF2 target genes and apoptosis in ER(+) cell lines. The prosurvival function of class IIa HDACs could be explained by the repression of NR4A1/Nur77, a proapoptotic MEF2 target. In summary, our studies underscore a contribution of class IIa HDACs to aggressiveness of ER(+) tumors.-Clocchiatti, A., Di Giorgio, E., Ingrao, S., Meyer-Almes, F.-J., Tripodo, C., Brancolini, C. Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER(+) breast tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159930     DOI: 10.1096/fj.12-209346

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  19 in total

Review 1.  Selective class IIa HDAC inhibitors: myth or reality.

Authors:  Eros Di Giorgio; Enrico Gagliostro; Claudio Brancolini
Journal:  Cell Mol Life Sci       Date:  2014-09-05       Impact factor: 9.261

2.  Transformation by different oncogenes relies on specific metabolic adaptations.

Authors:  Paolo Peruzzo; Marina Comelli; Eros Di Giorgio; Elisa Franforte; Irene Mavelli; Claudio Brancolini
Journal:  Cell Cycle       Date:  2016-08-02       Impact factor: 4.534

3.  The control operated by the cell cycle machinery on MEF2 stability contributes to the downregulation of CDKN1A and entry into S phase.

Authors:  Eros Di Giorgio; Enrico Gagliostro; Andrea Clocchiatti; Claudio Brancolini
Journal:  Mol Cell Biol       Date:  2015-03-02       Impact factor: 4.272

4.  Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription.

Authors:  Martina Minisini; Eros Di Giorgio; Emanuela Kerschbamer; Emiliano Dalla; Massimo Faggiani; Elisa Franforte; Franz-Josef Meyer-Almes; Rino Ragno; Lorenzo Antonini; Antonello Mai; Francesco Fiorentino; Dante Rotili; Monica Chinellato; Stefano Perin; Laura Cendron; Christian X Weichenberger; Alessandro Angelini; Claudio Brancolini
Journal:  Nucleic Acids Res       Date:  2022-03-21       Impact factor: 16.971

5.  HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3.

Authors:  Wei-Jie Zang; Yi-Lin Hu; Chen-Yu Qian; Ying Feng; Jia-Zhou Liu; Jun-Ling Yang; Hua Huang; Yi-Zhun Zhu; Wan-Jiang Xue
Journal:  Br J Cancer       Date:  2022-05-30       Impact factor: 9.075

6.  Synthesis and Characterization of Reversible Covalent HDAC4 Inhibitors.

Authors:  Anton Frühauf; Benjamin Wolff; Markus Schweipert; Franz-Josef Meyer-Almes
Journal:  Methods Mol Biol       Date:  2023

7.  MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation.

Authors:  Eros Di Giorgio; Andrea Clocchiatti; Sara Piccinin; Andrea Sgorbissa; Giulia Viviani; Paolo Peruzzo; Salvatore Romeo; Sabrina Rossi; Angelo Paolo Dei Tos; Roberta Maestro; Claudio Brancolini
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

8.  Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.

Authors:  Bhawna Rastogi; Satish K Raut; Naresh K Panda; Vidya Rattan; Bishan D Radotra; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2016-03-18       Impact factor: 3.396

9.  miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.

Authors:  Tsung-Hua Hsieh; Chia-Yi Hsu; Cheng-Fang Tsai; Cheng-Yu Long; Chee-Yin Chai; Ming-Feng Hou; Jau-Nan Lee; Deng-Chyang Wu; Shao-Chun Wang; Eing-Mei Tsai
Journal:  Oncotarget       Date:  2015-01-01

10.  Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.

Authors:  Marion Lapierre; Aurélien Linares; Mathieu Dalvai; Céline Duraffourd; Sandrine Bonnet; Abdelhay Boulahtouf; Carmen Rodriguez; Stéphan Jalaguier; Said Assou; Beatrice Orsetti; Patrick Balaguer; Thierry Maudelonde; Philippe Blache; Kerstin Bystricky; Nathalie Boulle; Vincent Cavaillès
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.